title: Treatment of inflammatory bowel disease: what's new in Digestive Disease Week 2016.
abstract: Inflammatory bowel disease is a chronic disorder of unknown aetiology that results from a pathologic response from both the innate and acquired immune systems, leading to chronic inflammation of the gastrointestinal tract. New drugs have been introduced into the therapeutic armamentarium of inflammatory bowel disease but are not effective in all patients; moreover, among initial responders, there have been reports of loss of response over time. In addition, these drugs sometimes have adverse effects and are often expensive. The present article reviews the studies presented at Digestive Disease Week 2016 that provided new data on the optimisation of currently approved treatments for inflammatory bowel disease, experience with recently approved drugs in clinical practice, and some studies on molecules that are under development for the treatment of these diseases.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España. Electronic address: mariachs2005@gmail.com.
authors.forename: María
authors.initials: M
authors.lastname: Chaparro
mesh_terms: D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000628:therapy*
keywords: Anti-TNF; Biosimilar; Colitis ulcerosa; Crohn disease; Células madre; Enfermedad de Crohn; Enfermedad inflamatoria intestinal; Faecal transplant; Immunosuppressants; Inflammatory bowel disease; Inmunosupresores; Stem cells; Tofacitinib; Trasplante fecal; Tratamiento; Treatment; Ulcerative colitis; Vedolizumab